Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hehlmann

Showing results (251-260 of 310) with videos related to

Pageof 31
Sort By:
Seminars in Hematology|February 4, 2003
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapyJ Hasford, M Pfirrmann, R Hehlmann, et al.
Leukemia|October 19, 2007
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratoriesM C Müller, P Erben, G Saglio, et al.
Investigational New Drugs|July 14, 2005
BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR)R-D Hofheinz, C Porta, G Hartung, et al.
Onkologie|November 6, 2001
Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancerG Hartung, R D Hofheinz, A Wein, et al.
British Journal of Cancer|July 9, 2004
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trialR-D Hofheinz, J T Hartmann, A Willer, et al.
British Journal of Haematology|April 1, 1997
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study GroupR Hehlmann, H Ansari, J Hasford, et al.
Leukemia|April 1, 2005
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1C Walz, A Chase, C Schoch, et al.
Haematologica|July 1, 1997
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemiaA M Carella, F Frassoni, J Melo, et al.
British Journal of Haematology|September 1, 1995
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alphaA Hochhaus, F Lin, A Reiter, et al.
Leukemia|June 24, 2000
Detection and quantification of residual disease in chronic myelogenous leukemiaA Hochhaus, A Weisser, P La Rosée, et al.
Pageof 31

Showing results (251-260 of 310) with videos related to

Sort By:
Pageof 31
Seminars in Hematology|February 4, 2003
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapyJ Hasford, M Pfirrmann, R Hehlmann, et al.
Leukemia|October 19, 2007
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratoriesM C Müller, P Erben, G Saglio, et al.
Investigational New Drugs|July 14, 2005
BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR)R-D Hofheinz, C Porta, G Hartung, et al.
Onkologie|November 6, 2001
Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancerG Hartung, R D Hofheinz, A Wein, et al.
British Journal of Cancer|July 9, 2004
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trialR-D Hofheinz, J T Hartmann, A Willer, et al.
British Journal of Haematology|April 1, 1997
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study GroupR Hehlmann, H Ansari, J Hasford, et al.
Leukemia|April 1, 2005
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1C Walz, A Chase, C Schoch, et al.
Haematologica|July 1, 1997
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemiaA M Carella, F Frassoni, J Melo, et al.
British Journal of Haematology|September 1, 1995
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alphaA Hochhaus, F Lin, A Reiter, et al.
Leukemia|June 24, 2000
Detection and quantification of residual disease in chronic myelogenous leukemiaA Hochhaus, A Weisser, P La Rosée, et al.
Pageof 31